Medicare Part B premiums expected to rise almost 10% in 2026

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

The Centers for Medicare and Medicaid Services and FDA announced a new coverage pathway—called the Regulatory Alignment for Predictable and Immediate Device, or RAPID pathway—designed to expedite access to certain FDA-designated Class II and Class III Breakthrough devices for people with Medicare.

April 24, 2026

Vol.52 No.16

Cancer Policy

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

The Centers for Medicare & Medicaid Services issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule, which aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior authorization, or ePA, requirements for covered prescription drugs and expedite federal response deadlines to ensure patients receive life-critical medications without administrative delay.

CMS proposes rule to update Medicare payments and transparency requirements for hospice care

The Centers for Medicare & Medicaid Services has proposed a rule to update Medicare payments for hospice care in the next fiscal year, which begins on Oct. 1.

Radiation oncologists hit hard after Medicare cuts, ASTRO survey finds

Two-thirds of radiation oncologists surveyed by the American Society for Radiation Oncology in March are seeing Medicare reimbursements decline by 10% or more, according to a report published on April 1.

ACA Marketplace enrollees are pinched by steeper healthcare costs, KFF follow-up survey finds

Four out of five people returning to the ACA Marketplace say their healthcare costs are “higher,” compared to last year, according to a survey conducted by Kaiser Family Foundation in mid-February and early March. More than half of respondents reported these costs (premiums, deductibles, co-pays, or coinsurance) were “a lot higher.”

PanTracer LBx liquid biopsy profiling test receives Medicare coverage

NeoGenomics announced the PanTracer LBx test has received coverage from CMS’ Molecular Diagnostics Services Program under Local Coverage Determination - MolDX: Plasma-Based Genomic Profiling in Solid Tumors.

March 20, 2026

Vol.52 No.11

Medicare Part B premiums expected to rise almost 10% in 2026

YOU MAY BE INTERESTED IN

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

CMS proposes rule to update Medicare payments and transparency requirements for hospice care

Radiation oncologists hit hard after Medicare cuts, ASTRO survey finds

ACA Marketplace enrollees are pinched by steeper healthcare costs, KFF follow-up survey finds

PanTracer LBx liquid biopsy profiling test receives Medicare coverage

Renew today!

Subscriber content

Never miss an issue!

Login